Anabolic agents are currently being Doramapimod molecular weight used “off label” for some disorders that are not included in their Summaries of Product Characteristics, such as fracture consolidation delay, pseudoarthrosis, after prosthesis implants or total joint replacement, aseptic prosthesis loosening, Südeck’s algodystrophy, acute vertebral fractures with poor pain control, or peri-prosthetic fracture. Despite unproven efficacy in such conditions, therapy is often administered for some months (until clinical resolution of underlying causes), and sometimes for up to 24 months. Current Needs and Opportunities for Improvement in Organizational Issues Some recommendations were provided regarding the need

for improvement in organizational issues, including the following: The cost implications of therapy are recognized in a finite-resource scenario, particularly in the present context of a deep economic crisis.

Taking into account that available treatments for osteoporosis have proved to be efficient in reducing fracture incidence and complications, available resources should be used in the most efficient way. Thus, such Selleck GSK690693 therapies should be used in patients with a significant fracture risk and during life periods when such a risk is really apparent. Use of strong anti-osteoporotic treatments PF-6463922 nmr in low-risk patients is unreasonable, whereas therapy denial or failure to recognize disease occurrence in patients at risk is irresponsible. A multidisciplinary team approach is recommended for osteoporotic patients; such teams would be particularly effective when treating HRF patients. ○ Current interest in osteoporosis is highly variable across medical specialties and geographic areas. No general rule can be established as to which medical specialists are most suitable for the care of osteoporotic patients. ○ One situation that needs to be improved is patient care after admission with an osteoporotic fracture; a large number of patients do not receive the correct diagnosis and therapy after initial treatment of the

acute event. Such patients show high bone fragility and would mostly benefit from appropriate management. ○ At least some members of medical departments currently treating patients with prevalent fractures or HRF patients (orthopedic IMP dehydrogenase surgery, rehabilitation, geriatrics, and others) should be involved in protocol development for osteoporotic patient care. ○ Primary care physicians should be involved in the diagnosis, treatment, and follow-up of patients initially treated by other specialists (such as orthopedic surgeons). Agreed patient selection processes should be established. There is an obvious need for better information flow across care levels through clinical reports and regular meetings or dedicated multilevel teams. Densitometer availability is highly variable.